The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices
 

Alnylam Pharmaceuticals Inc

Nasdaq: ALNY
Last

(U.S.) $67.72

Today's change+0.91 +1.36%
Updated July 27 12:17 PM EDT. Delayed by at least 15 minutes.
 

Alnylam Pharmaceuticals Inc

Nasdaq: ALNY
Last

(U.S.) $67.72

Today's change+0.91 +1.36%
Updated July 27 12:17 PM EDT. Delayed by at least 15 minutes.

Alnylam Pharmaceuticals Inc Hits New 20-day High

Alnylam Pharmaceuticals Inc is up today by (U.S.)$0.91 or 1.36% to (U.S.)$67.72 and setting a new 20-day high. Over the last five days, shares have gained 3.01%, but are down 28.06% for the last year to date. Shares have underperformed the S&P 500 by 52.05% during the last year.

Key company metrics

  • Open(U.S.) $66.98
  • Previous close(U.S.) $66.81
  • High(U.S.) $68.35
  • Low(U.S.) $66.98
  • Bid / Ask(U.S.) $67.62 / (U.S.) $67.72
  • YTD % change-28.06%
  • Volume247,105
  • Average volume (10-day)1,050,460
  • Average volume (1-month)1,010,497
  • Average volume (3-month)948,835
  • 52-week range(U.S.) $49.96 to (U.S.) $132.00
  • Beta2.52
  • Trailing P/ENegative, not meaningful
  • P/E 1 year forwardNegative, not meaningful
  • Forward PEGNegative, not meaningful
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) -$4.03
Updated July 27 12:17 PM EDT. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
-1,144.52%

Although this company's net profit margin is negative, it is above the industry average and implies that Alnylam Pharmaceuticals Inc is operating more effectively than other companies in the industry.
Company Books

S&P TSX0.42%Sector:HealthcareIndustry:Biotechnology
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q1/2016Q4/2015Q3/2015Q2/2015
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedMar 31, 201603/31/2016Dec 31, 201512/31/2015Sep 30, 201509/30/2015Jun 30, 201506/30/2015
Revenue7869
Total other revenue--------
Total revenue7869
Gross profit--------
Total cost of revenue--------
Total operating expense1171008582
Selling / general / administrative21171615
Research & development96836967
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)--------
Other operating expenses, total--------
Operating income-110-93-78-73
Interest income (expense), net non-operating--------
Gain (loss) on sale of assets--------
Other--------
Income before tax-103-91-77-71
Income after tax-103-91-77-72
Income tax, total0000
Net income-103-91-77-72
Total adjustments to net income--------
Net income before extra. items-103-91-77-72
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items-103-91-77-72
Inc. avail. to common incl. extra. items-103-91-77-72
Diluted net income-103-91-77-72
Dilution adjustment--------
Diluted weighted average shares85858584
Diluted EPS excluding extraordinary itemsvalue per share-1.21-1.07-0.91-0.85
Dividends per sharevalue per share0.000.000.000.00
Diluted normalized EPSvalue per share-1.21-1.07-0.91-0.85